BridgeBio Pharma, Inc.

BBIO

US10806X1028

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
24.88 ^USD	+2.26%		+0.57%	-38.37%

Apr. 07	BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	CI
Mar. 20	JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	MT

BridgeBio Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 22, 2024 at 07:30 am EST

BridgeBio Pharma, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 1.75 million compared to USD 1.87 million a year ago. Net loss was USD 168.15 million compared to USD 137.59 million a year ago.

Latest news about BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	Apr. 07	CI
JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	Mar. 20	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $70 From $60, Maintains Overweight Rating	Mar. 19	MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Overweight Rating	Mar. 11	MT
BridgeBio Pharma Prices $250 Million Stock Offering	Mar. 06	MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Mar. 05	MT
BridgeBio Pharma Commences $250 Million Share Offering	Mar. 04	MT
Mizuho Securities Trims Price Target on BridgeBio Pharma to $53 From $60, Keeps Buy Rating	Mar. 04	MT
BridgeBio Pharma Sells License for Potential Heart Disease Treatment to Bayer in Deal Worth up to $310 Million	Mar. 04	MT
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe	Mar. 04	RE
Bridgebio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	Mar. 04	CI
Citigroup Adjusts BridgeBio Pharma Price Target to $46 From $42, Maintains Buy Rating	Feb. 23	MT
Citigroup Adjusts Price Target on BridgeBio Pharma to $46 From $42, Keeps Buy Rating	Feb. 23	MT
BridgeBio Pharma Q4 Loss Widens as Revenue Declines	Feb. 22	MT
BridgeBio Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q4 Revenue $1.7M	Feb. 22	MT
BridgeBio Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
KKR to acquire a stake in health tech firm Cotiviti	Feb. 14	RE
BridgeBio Pharma Unit to Grant Kyowa Kirin License for Infigratinib in Japan	Feb. 07	MT
Bridgebio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan	Feb. 07	CI
BridgeBio Pharma Says US FDA Accepts New-Drug Application for Transthyretin Amyloid Cardiomyopathy Treatment	Feb. 05	MT
BridgeBio Pharma Gets FDA Acceptance for NDA of Acoramidis	Feb. 05	DJ
BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy	Feb. 05	CI
AstraZeneca Says Phase 3 Trial of Acoramidis in Japan Well-Tolerated; Shows Consistency With Global Trial	Feb. 02	MT
BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months	Feb. 02	CI

Chart BridgeBio Pharma, Inc.

Duration

Period

More charts

Company Profile

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

Sector

Pharmaceuticals

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for BridgeBio Pharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.88 USD

Average target price

50.75 USD

Spread / Average Target

+103.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BRIDGEBIO PHARMA, INC.	-38.37%	4.66B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B

Biopharmaceuticals